National Cancer Institute; Notice of Meeting, 8210 [2021-02298]
Download as PDF
<![CDATA[
8210
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIGMS Initial Review
Group; Training and Workforce Development
Subcommittee—D To Review MARC, U–RISE
and G–RISE Applications.
Date: March 9, 2021.
Time: 10:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Video Meeting).
Contact Person: Tracy Koretsky, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, MSC 6200, Room 3AN.12F,
Bethesda, MD 20892, (301) 594 2886,
tracy.koretsky@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: January 29, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02308 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
jbell on DSKJLSW7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
amended, notice is hereby given of a
meeting of the National Cancer Institute
Clinical Trials and Translational
Research Advisory Committee.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: March 17, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Cancer Institute, 9609
Medical Center Drive, Rockville, MD 20850
(Virtual Meeting).
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, National Cancer Institute,
National Institutes of Health, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Multi-Center
Clinical Trial Cooperative Agreement (U01
Clinical Trial Required).
Date: March 2, 2021.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A. Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
6707 Democracy Boulevard, Room 7119,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: January 29, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02306 Filed 2–3–21; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2021–02298 Filed 2–3–21; 8:45 am]
National Eye Institute; Amended Notice
of Meeting
National Institutes of Health
Notice is hereby given of a change in
the meeting of the National Advisory
Eye Council, February 12, 2021, 10:00
a.m. to 4:00 p.m., National Eye Institute,
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
Jkt 253001
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Meeting
17:13 Feb 03, 2021
National Institutes of Health
Dated: January 27, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 86, Number 22 (Thursday, February 4, 2021)]
[Notices]
[Page 8210]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02298]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Institute Clinical Trials and Translational Research Advisory
Committee.
The meeting will be held as a virtual meeting and is open to the
public. Individuals who plan to view the virtual meeting and need
special assistance or other reasonable accommodations to view the
meeting, should notify the Contact Person listed below in advance of
the meeting. The meeting will be videocast and can be accessed from the
NIH Videocasting and Podcasting website (https://videocast.nih.gov).
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: March 17, 2021.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: Strategic Discussion of NCI's Clinical and Translational
Research Programs.
Place: National Cancer Institute, 9609 Medical Center Drive,
Rockville, MD 20850 (Virtual Meeting).
Contact Person: Sheila A. Prindiville, MD, MPH, Director,
Coordinating Center for Clinical Trials, National Cancer Institute,
National Institutes of Health, 9609 Medical Center Drive, Room
6W136, Rockville, MD 20850, 240-276-6173, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: January 27, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-02298 Filed 2-3-21; 8:45 am]
BILLING CODE 4140-01-P
